Hospital
Lasalle Parish Hospital Service Dist No1
Lasalle Parish Hospital Service Dist No1 was paid $5.29M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoLASALLE PARISH HOSPITAL SERVICE DIST NO1
OLLA, LA 71465
OLLA, LA 71465
33aNPI1639263189assigned 10/02/2006
33bProvider typeCritical Access Hospital
28Total paid$5.29M
24GClaims110,422
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#11 of 40
Median peer was paid$3.19M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,300 | $565K | |
| 2019 | 11,524 | $581K | |
| 2020 | 11,541 | $484K | |
| 2021 | 16,958 | $834K | |
| 2022 | 21,000 | $978K | |
| 2023 | 21,795 | $1.14M | |
| 2024incomplete | 16,304 | $710K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 6,802 | 5,815 | $2.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 8,173 | 7,294 | $1.28M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.8% | 9,185 | 7,979 | $305K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.6% | 17,511 | 8,199 | $246K |
| 71046 | Radiologic examination, chest; 2 views | 2.6% | 1,298 | 1,104 | $137K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2.5% | 465 | 432 | $132K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 205 | 176 | $123K |
| G0378 | Hospital observation service, per hour | 1.8% | 141 | 110 | $95K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 375 | 200 | $79K |
| 87430 | 1.4% | 5,381 | 4,917 | $74K | |
| 71045 | Radiologic examination, chest; single view | 1.3% | 1,031 | 896 | $71K |
| 80050 | General health panel | 1.1% | 1,436 | 1,308 | $58K |
102 more codes
| J3490 | Unclassified drugs | 1.1% | 3,405 | $57K |
| 73630 | 1.0% | 501 | $55K | |
| 80053 | Comprehensive metabolic panel | 1.0% | 7,047 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,668 | $45K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 637 | $42K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 10,880 | $37K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 174 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 121 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,229 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 62 | $25K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 191 | $23K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 956 | $19K |
| A0425 | Ground mileage, per statute mile | <1% | 127 | $18K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,082 | $17K |
| 87420 | <1% | 1,311 | $16K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,857 | $14K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 96 | $11K |
| 85027 | <1% | 2,111 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 244 | $9K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 48 | $9K |
| 80061 | Lipid panel | <1% | 799 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 303 | $7K |
| 84436 | <1% | 1,196 | $6K | |
| 82670 | <1% | 257 | $6K | |
| 84479 | <1% | 1,198 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 79 | $6K |
| 81001 | <1% | 2,604 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 336 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 711 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 94 | $5K |
| 93307 | <1% | 32 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 39 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 363 | $4K |
| 83001 | <1% | 253 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 66 | $4K |
| 84403 | <1% | 147 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 62 | $2K |
| 87486 | <1% | 62 | $2K | |
| 87581 | <1% | 62 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,031 | $2K |
| 94664 | <1% | 180 | $2K | |
| 83880 | <1% | 70 | $2K | |
| 82172 | <1% | 89 | $1K | |
| 99220 | <1% | 12 | $1K | |
| 74018 | <1% | 15 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 326 | $1K |
| 84484 | <1% | 164 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 30 | $1K |
| 86003 | <1% | 26 | $970.83 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 334 | $956.86 |
| 83010 | <1% | 88 | $952.15 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 129 | $885.11 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 80 | $877.37 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 269 | $840.37 |
| 90686 | <1% | 32 | $800.40 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 26 | $734.03 |
| 0002A | <1% | 24 | $730.80 | |
| 82150 | <1% | 160 | $717.36 | |
| 11721 | <1% | 52 | $700.14 | |
| 82553 | <1% | 116 | $679.27 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 31 | $547.00 |
| 86140 | <1% | 146 | $489.49 | |
| 82977 | <1% | 77 | $471.46 | |
| 11056 | <1% | 19 | $450.09 | |
| J2704 | Injection, propofol, 10 mg | <1% | 693 | $444.75 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $433.94 |
| 86308 | <1% | 89 | $422.08 | |
| 87070 | <1% | 61 | $417.85 | |
| 0001A | <1% | 33 | $413.92 | |
| 83883 | <1% | 75 | $406.87 | |
| 81025 | <1% | 56 | $386.18 | |
| 84550 | <1% | 119 | $385.16 | |
| 84478 | <1% | 74 | $352.90 | |
| 85651 | <1% | 110 | $325.46 | |
| 82465 | <1% | 74 | $263.09 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $260.72 |
| 82550 | <1% | 76 | $247.20 | |
| 87040 | <1% | 29 | $246.75 | |
| 86800 | <1% | 17 | $240.17 | |
| 86376 | <1% | 17 | $219.64 | |
| 84439 | <1% | 23 | $207.46 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20 | $196.92 |
| 84460 | <1% | 42 | $183.15 | |
| 84450 | <1% | 42 | $178.99 | |
| 87088 | <1% | 32 | $178.96 | |
| 82607 | <1% | 13 | $167.57 | |
| 82247 | <1% | 42 | $158.72 | |
| 91300 | <1% | 56 | $148.32 | |
| 82947 | <1% | 42 | $135.81 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 40 | $109.40 |
| 83550 | <1% | 15 | $89.92 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21 | $77.17 |
| 82043 | <1% | 14 | $63.58 | |
| 88160 | <1% | 92 | $45.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 233 | $29.15 |
| 99000 | <1% | 380 | $8.64 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 264 | $0.00 |
| 85060 | 0% | 188 | $0.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 265 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 80 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHEWS, PAUL (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Lasalle Parish Hospital Service District #1 | Olla, LA | $19.63M |
| Lasalle Parish Hospital Service District #1 | Urania, LA | $11.53M |
| Lasalle Parish Hospital Service District #1 | Olla, LA | $541.66 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.